Oxford Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-3,051
| Closed | -$337K | – | 654 |
|
|
2025
Q1 | $337K | Buy |
+3,051
| New | +$337K | 0.16% | 215 |
|
|
2024
Q4 | – | Sell |
-7,777
| Closed | -$896K | – | 549 |
|
|
2024
Q3 | $896K | Buy |
7,777
+4,578
| +143% | +$527K | 0.75% | 21 |
|
|
2024
Q2 | $440K | Buy |
+3,199
| New | +$440K | 0.43% | 63 |
|
|
2020
Q1 | – | Sell |
-39,120
| Closed | -$4.21M | – | 894 |
|
|
2019
Q4 | $4.21M | Buy |
39,120
+27,770
| +245% | +$2.98M | 0.12% | 189 |
|
|
2019
Q3 | $1.02M | Buy |
+11,350
| New | +$1.02M | 0.02% | 931 |
|
|
2018
Q4 | – | Sell |
-7,346
| Closed | -$892K | – | 1972 |
|
|
2018
Q3 | $892K | Buy |
+7,346
| New | +$892K | 0.02% | 1059 |
|
|
2018
Q2 | – | Sell |
-25,974
| Closed | -$2.15M | – | 1842 |
|
|
2018
Q1 | $2.15M | Buy |
25,974
+3,251
| +14% | +$270K | 0.05% | 531 |
|
|
2017
Q4 | $1.76M | Buy |
+22,723
| New | +$1.76M | 0.04% | 643 |
|
|
2017
Q2 | – | Sell |
-39,340
| Closed | -$1.7M | – | 1619 |
|
|
2017
Q1 | $1.7M | Sell |
39,340
-20,103
| -34% | -$870K | 0.04% | 566 |
|
|
2016
Q4 | $2.3M | Buy |
+59,443
| New | +$2.3M | 0.08% | 285 |
|
|
2013
Q4 | – | Sell |
-211,439
| Closed | -$2.39M | – | 758 |
|
|
2013
Q3 | $2.39M | Buy |
+211,439
| New | +$2.39M | 0.05% | 408 |
|